PT  - JOURNAL ARTICLE
AU  - Renaud Louis
AU  - Pascal Chanez
AU  - Francesco Menzella
AU  - George Philteos
AU  - Borja G Cosio
AU  - Njira L. Lugogo
AU  - Gustavo De Luiz
AU  - Tim Harrison
AU  - Annie Burden
AU  - Timothy Adlington
AU  - Nanna Keeling
AU  - Justin Kwiatek
AU  - Esther Garcia Gil
TI  - Late Breaking Abstract - Standard-of-Care Asthma Controller Regimen Reduction with Benralizumab Treatment: ANDHI In Practice Study
AID  - 10.1183/13993003.congress-2021.PA1114
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA1114
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA1114.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA1114.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Rationale: To assess the potential to reduce standard-of-care asthma controller medication while maintaining asthma control with benralizumab.Methods: At the completion of the 24-week, double-blind, randomized, placebo-controlled phase 3b ANDHI study, eligible adults with severe, eosinophilic asthma (SEA) were enrolled in the 56-week, ANDHI in Practice open-label extension. Concomitant asthma therapies were tapered for patients achieving and maintaining sufficient asthma control with benralizumab (Asthma Control Questionnaire-6 [ACQ-6] <1.5, no increase in ACQ-6 ≥0.5, and exacerbation-free). After an 8-week run-in, there were 5 visits every 8 weeks to potentially reduce background medication. Main outcome measures (summarized descriptively) were the proportion of patients with reductions in one or more asthma medications and achieving increasing numbers of GINA step reductions at end of trial (EOT) for non-OCS dependent patients. Percentage reductions in daily OCS dosage was the main measure for OCS-dependent patients.Results: A total of 53.3% (n=208/390) of non-OCS dependent patients treated with benralizumab successfully achieved ≥1 background medication reductions. In those patients with asthma control at EOT (n=179), 72.6% (n=130) achieved background therapy reductions. 42% (n=163) of patients achieved ≥1 GINA step reductions from baseline to EOT, increasing to 62% (n=110) in patients with asthma control at EOT. In the OCS dependent group, 51% (n=50/99) eliminated OCS use by EOT.Conclusions: Patients with SEA treated with benralizumab successfully had reductions in both OCS and non-OCS background therapies as well as GINA step reductions.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1114.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).